Evidence map›Paper›PMID 28791438›Full record

ArticleJournal of molecular medicine (Berlin, Germany)2017

VPS52 induces apoptosis via cathepsin D in gastric cancer.

Jian Zhang, Ying Lin, Xichun Hu, Zheng Wu, Weijian Guo

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular medicine (Berlin, Germany), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. GARP Complex in Golgi Physiology.Sub-cellular biochemistry · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. International journal of molecular sciences · 2023
    Article
  6. Article
  7. Role of GARP Vesicle Tethering Complex in Golgi Physiology.International journal of molecular sciences · 2023
    Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jian ZhangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, No. 270 Dong'an Rd, Shanghai, 200032, People's Republic of China. syner2000@163.com.
Ying LinDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, No. 270 Dong'an Rd, Shanghai, 200032, People's Republic of China.
Xichun HuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, No. 270 Dong'an Rd, Shanghai, 200032, People's Republic of China.
Zheng WuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, No. 270 Dong'an Rd, Shanghai, 200032, People's Republic of China.
Weijian GuoDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, No. 270 Dong'an Rd, Shanghai, 200032, People's Republic of China.
Fudan University Shanghai Cancer Center · CNShanghai Medical College of Fudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vacuolar protein sorting (VPS) genes encode a class of proteins involved in vesicular trafficking. Growing evidence suggests that VPS proteins play roles in tumor biology. Vacuolar protein sorting 52 (VPS52) is involved in retrograde transport of endosomes, and its roles in cancers have not been explored. This study investigated the genetic alterations, protein changes, biological role, and molecular mechanism of VPS52 in gastric cancer. Loss of heterozygosity of VPS52 was detected in 52.9% (9/17) of gastric cancer samples. Twenty-five percent (5/20) gastric cancer samples contained somatic stop-gain mutation of VPS52, two of which also had simultaneous loss of heterozygosity. Lack of VPS52 protein expression in gastric cancer tissue was found compared with pericancerous tissue and was significantly correlated with more advanced TNM staging and shorter 3-year overall survival. Overexpression of VPS52 significantly reduced viability and increased apoptosis in gastric cancer cells in vitro and reduced tumor volume and tumor weight in xenograft model in vivo. Activation of the cathepsin D/Bax/cytochrome C/caspase 9/caspase 3 pathway was detected in gastric cancer cells overexpressing VPS52. Collectively, VPS52 is a tumor suppressor gene in gastric cancer and could be used as a biomarker. VPS52 adenovirus could be a novel anti-tumor reagent for future gene therapy. KEY MESSAGES: Loss of heterozygosity and stop-gain mutation of VPS52 were found in gastric cancer. Negative expression of VPS52 significantly correlated with poor prognosis. VPS52 inhibited viability and induced apoptosis of gastric cancer cells in vitro. VPS52 reduced tumor volume and tumor weight in vivo. VPS52 activated the apoptotic pathway through cathepsin D in gastric cancer cells.

Indexed as

ApoptosisCathepsin DCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansLoss of HeterozygosityMaleMiddle AgedMutationSignal TransductionStomach NeoplasmsVesicular Transport ProteinsCathepsin DVesicular Transport ProteinsVPS52 protein, humanApoptosisCathepsin DGastric cancerTumor suppressor geneVacuolar protein sorting 52

Identifiers

PMID28791438
OpenAlexW2743699909

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.